ClinOne’s published compliance rate with patient self-dosing compliance is 97% at 10 months with the Dosing Manager module, a major asset to clinical trial sponsors.
Since clinical trials rely on precision in self-dosing to keep trials on track and patients compliant, ClinOne’s Dosing Manager solves for this and does so extremely effectively.
The typical pain points and associated ClinOne benefits include:
Without ClinOne technology, the published data for dosing compliance is just 75% at 3 months on trial, and drops to 60% at the 10th month on trial.
The ClinOne solution increases compliance up to 97% throughout 12 months.
To increase patient dosing visibility: sites receive reports designed to focus on patients where non-compliance is a concern, allowing for dosage-focused monitoring visits where needed.
The technology provides automated weekly compliance reports to the research site coordinator, including helping identify patients that may require direct site contact to address poor compliance.
With this highly effective means of engaging the patient and driving better self-dosing compliance – consistently up to 97% — Dosing Manager is the perfect solution.